In the last trading session, 1.3 million shares of the Kairos Pharma Ltd (AMEX:KAPA) were traded. Most recently the company’s share price was $0.57, and it changed around $0.03 or 6.36% from the last close, which brings the market valuation of the company to $9.69M. KAPA currently trades at a discount to its 52-week high of $4.00, offering almost -601.75% off that amount. The share price’s 52-week low was $0.40, which indicates that the current value has risen by an impressive 29.82% since then. We note from Kairos Pharma Ltd’s average daily trading volume that its 10-day average is 2.51 million shares, with the 3-month average coming to 695.75K.
Kairos Pharma Ltd stock received a consensus recommendation rating of Overweight, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended KAPA as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight.
Kairos Pharma Ltd (AMEX:KAPA) trade information
Instantly KAPA has showed a green trend with a performance of 6.36% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.6250 on recent trading dayincreased the stock’s daily price by 8.8%. The company’s shares are currently down -62.18% year-to-date, but still up 5.68% over the last five days. On the other hand, Kairos Pharma Ltd (AMEX:KAPA) is -7.42% down in the 30-day period. We can see from the shorts that 19410.0 shares have been sold at a short interest cover period of 0.08 day(s).
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -23.37%. Kairos Pharma Ltd earnings are expected to increase by 7.25% in 2025, but the outlook is negative -24.45% per year for the next five years.
KAPA Dividends
Kairos Pharma Ltd’s next quarterly earnings report is expected to be released on 2025-May-13.
Kairos Pharma Ltd (AMEX:KAPA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 47.25% of Kairos Pharma Ltd shares, and 9.36% of them are in the hands of institutional investors. The stock currently has a share float of 17.75%.
